Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France.
Fiche publication
Date publication
avril 2020
Journal
Digestive diseases and sciences
Auteurs
Membres identifiés du Cancéropôle Est :
Pr THIEFIN Gérard
Tous les auteurs :
Ouzan D, Larrey D, Guyader D, Remy AJ, Riachi G, Heluwaert F, Truchi R, Combis JM, Bailly F, Rosa I, Hézode C, Glorian-Petraud D, Libert O, Ramroth H, Asselah T, Thiefin G, Roulot D, Roche B, Leroy V, Dumortier J, Thabut D, Pol S,
Lien Pubmed
Résumé
Treatment of hepatitis C virus (HCV) has been dramatically improved with the introduction of direct-acting antiviral agents (DAAs). Universal access to pangenotypic DAAs was provided in France from 2017, expanding the type of patients treated. Real-world studies are important to confirm effectiveness and safety in clinical practice, particularly in vulnerable populations.
Mots clés
France, Hepatitis C, Practice guidelines as topic, Sofosbuvir, Treatment outcome
Référence
Dig. Dis. Sci.. 2020 Apr 18;: